Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Kyorin: New Products Drive Increases in 1st-half Sales, Profits
December 2, 2002
- Azwell: "Painful Reforms" Bring Return to Profitability
December 2, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 2, 2002
- Mochida: NHI Price Cuts Affect Semiannual Sales, Profits
December 2, 2002
- Toho: Cost-cutting, Higher Margins Boost Sales, Profits
December 2, 2002
- Meiji Seika Discovers Enzymes Inactivating Abnormal Prion Protein
December 2, 2002
- Rohto: Profits Jump Despite Modest Increase in Sales
December 2, 2002
- Tanabe Seiyaku to Co-develop Altana's Roflumilast
December 2, 2002
- DIAGNOSTIC NEWS IN BRIEF
December 2, 2002
- Kissei: NHI Price Cut, Sluggish Sales Hit Sales, Profits
December 2, 2002
- Nippon Shinyaku's Cylocide Gets New Indication for Malignant Lymphoma
December 2, 2002
- World Self-Medication Industry 14th General Assembly & 5th Asia Pacific Regional Conference
December 2, 2002
- Zeria: Ethical Drug Sales Down 8.9% in First Half
December 2, 2002
- WEBSITE NEWS
December 2, 2002
- WG to Recommend OTC Drugs to Prevent Lifestyle-related Diseases
December 2, 2002
- Fuso: Sales, Profits Down Due to Lower Sales of Dialysis Products
December 2, 2002
- Otsuka's Schizophrenia Treatment Abilify Obtains Approvable Letter from FDA
December 2, 2002
- Sundrug: Strong Sales Support Expansion Beyond Tokyo Metropolitan Area
December 2, 2002
- Wakamoto: Profits Plummet Due to Increased Costs, R&D Investment
December 2, 2002
- Otsuka Licenses Antiparkinson Drug from Schwarz
December 2, 2002
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…